TOKYO, May 20, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today confirmed the U.S. District Court for the District of Delaware ruling that all asserted claims of the 8,106,183; 8, 524,883; and RE47301 patents for LEXISCAN® (regadenoson injection) 0.4 mg/mL are not infringed. The patent infringement trial involved one Abbreviated New Drug Application (ANDA) filer, Hospira, Inc. Hospira is requesting permission from FDA to manufacture and commercialize a generic LEXISCAN® product before expiration of the LEXISCAN® patents. Astellas plans to appeal the decision and to take legal action to prevent Hospira from launching generic LEXISCAN® pending resolution of the appeal.

Astellas is reviewing the potential financial impacts of this district court decision for the fiscal year ending March 31, 2023.

Click below for a copy of the full press release

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Astellas Pharma Inc. published this content on 20 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 May 2022 23:44:03 UTC.